Adalvo is pleased to announce the successful DCP Submission for Drospirenone + Ethinylestradiol.
Drospirenone + Ethinylestradiol has been developed, in collaboration with one of our strategic partners, based on the reference brand Yasmin. The product is a low dose oral contraceptive.
According to IQVIA, the INN generated approximately $817mio in global sales in 2022.
Adalvo has entered into a strategic collaboration with a leading partner specializing in women's health, aiming to enhance our offerings in the hormonal products domain. This collaboration expands our portfolio to include a diverse range of oral contraceptives and hormonal replacement products. We are equipped to provide our partners with a comprehensive selection of these products on a global scale.
Our women's health products include:
- Dienogest, 2 mg
- Levonorgestrel, 1,5 mg
- Levonorgestrel+ Ethinylestradiol, 0.10mg+0.02mg
- Levonorgestrel+ Ethinylestradiol, 0.15mg+0.03mg
- Drospirenone + Ethinylestradiol, 3mg+0.03mg
- Drospirenone + Ethinylestradiol, 3mg+0.02mg
- Desogestrel + Ethinylestradiol, 0.10 mg + 0.02 mg
- Desogestrel + Ethinylestradiol, 0.15mg+0.03mg
- Norethisterone + Estradiol, 0.5mg+1mg
- Norethisterone, 5 mg
- Desogestrel, 75 mcg
- Cyproterone + Ethinylestradiol, 2 mg + 0.035 mg
- Dydrogesterone, 10mg
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
email@example.com – Central & Eastern Europe, Russia & CIS
firstname.lastname@example.org- North Europe, APAC, MENA & Israel
email@example.com – Brazil
firstname.lastname@example.org - LATAM (exc. Brazil) & South Europe
email@example.com – Europe
firstname.lastname@example.org – UK/Ireland, North America & South Africa
email@example.com - Head of Global BD&L
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.